CA2573271C
(en)
|
2004-07-15 |
2015-10-06 |
Amr Technology, Inc. |
Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
|
CN101395155A
(en)
*
|
2005-10-07 |
2009-03-25 |
埃克塞里艾克西斯公司 |
Pyridopyrimidinone inhibitors of pi3k alpha
|
PT3184526T
(en)
|
2005-12-13 |
2018-12-19 |
Incyte Holdings Corp |
Pyrrolo[2,3-d]pyrimidine derivatives as janus kinase inhibitor
|
TW200817410A
(en)
|
2006-08-07 |
2008-04-16 |
Incyte Corp |
Triazolotriazines as kinase inhibitors
|
WO2008030579A2
(en)
*
|
2006-09-07 |
2008-03-13 |
Biogen Idec Ma Inc. |
Irak modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder
|
WO2008051757A1
(en)
*
|
2006-10-20 |
2008-05-02 |
Irm Llc |
Compositions and methods for modulating c-kit and pdgfr receptors
|
ME02372B
(en)
|
2006-11-22 |
2016-06-20 |
Incyte Holdings Corp |
Imidazotriazines and imidazopyrimidines as kinase inhibitors
|
AR067326A1
(en)
*
|
2007-05-11 |
2009-10-07 |
Novartis Ag |
IMIDAZOPIRIDINES AND PIRROLO -PIRIMIDINES REPLACED AS INHIBITORS OF LIPIDO KINASE
|
US20080312259A1
(en)
|
2007-06-13 |
2008-12-18 |
Incyte Corporation |
SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE
|
FR2918061B1
(en)
|
2007-06-28 |
2010-10-22 |
Sanofi Aventis |
6-CYCLOAMINO-3- (PYRIDIN-4-YL) IMIDAZO-1,2-B1-PYRIDAZINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE.
|
JP5774982B2
(en)
*
|
2008-05-19 |
2015-09-09 |
サノビオン ファーマシューティカルズ インクSunovion Pharmaceuticals Inc. |
Imidazo [1,2-a] pyridine compound
|
TWI472529B
(en)
|
2008-05-21 |
2015-02-11 |
Incyte Corp |
Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
|
US9156812B2
(en)
|
2008-06-04 |
2015-10-13 |
Bristol-Myers Squibb Company |
Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
|
AR071997A1
(en)
*
|
2008-06-04 |
2010-07-28 |
Bristol Myers Squibb Co |
CRYSTAL FORM OF 6 - ((4S) -2-METHYL-4- (2-NAFTIL) -1,2,3,4-TETRAHYDROISOQUINOLIN-7-IL) PIRIDAZIN-3-AMINA
|
TWI496779B
(en)
*
|
2008-08-19 |
2015-08-21 |
Array Biopharma Inc |
Triazolopyridine compounds as pim kinase inhibitors
|
US8987251B2
(en)
|
2008-08-19 |
2015-03-24 |
Array Biopharma Inc. |
Triazolopyridine compounds as PIM kinase inhibitors
|
WO2010022081A1
(en)
*
|
2008-08-19 |
2010-02-25 |
Array Biopharma Inc. |
Triazolopyridine compounds as pim kinase inhibitors
|
US8895550B2
(en)
|
2008-08-19 |
2014-11-25 |
Array Biopharma Inc. |
Triazolopyridine compounds as PIM kinase inhibitors
|
CN103965200B
(en)
|
2008-09-22 |
2016-06-08 |
阵列生物制药公司 |
As imidazo [1,2-B] pyridazine compound of the replacement of TRK kinase inhibitor
|
CL2009001884A1
(en)
*
|
2008-10-02 |
2010-05-14 |
Incyte Holdings Corp |
Use of 3-cyclopentyl-3- [4- (7h-pyrrolo [2,3-d] pyrimidin-4-yl) -1h-pyrazol-1-yl) propanonitrile, janus kinase inhibitor, and use of a composition that understands it for the treatment of dry eye.
|
LT3372605T
(en)
|
2008-10-22 |
2022-02-10 |
Array Biopharma, Inc. |
Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
|
WO2010132437A1
(en)
|
2009-05-12 |
2010-11-18 |
Albany Molecular Research, Inc. |
Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
|
AU2010249493A1
(en)
*
|
2009-05-20 |
2011-12-08 |
Cylene Pharmaceuticals, Inc. |
Pyrazolopyrimidines and related heterocycles as kinase inhibitors
|
ES2487542T3
(en)
*
|
2009-05-22 |
2014-08-21 |
Incyte Corporation |
N- (hetero) aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo [2,3-d] pyrimidines and pyrrol-3-yl-pyrrolo [2,3-d] pyrimidines as Janus kinase inhibitors
|
CN106967070A
(en)
|
2009-05-22 |
2017-07-21 |
因塞特控股公司 |
It is used as the compound of JAK inhibitor
|
AR077468A1
(en)
|
2009-07-09 |
2011-08-31 |
Array Biopharma Inc |
PIRAZOLO COMPOUNDS (1,5-A) PYRIMIDINE SUBSTITUTED AS TRK-QUINASA INHIBITORS
|
AR078012A1
(en)
|
2009-09-01 |
2011-10-05 |
Incyte Corp |
HETEROCICLIC DERIVATIVES OF PIRAZOL-4-IL-PIRROLO (2,3-D) PYRIMIDINS AS INHIBITORS OF THE QUANASA JANUS
|
US9227971B2
(en)
|
2010-01-19 |
2016-01-05 |
Merck Sharp & Dohme Corp. |
Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors
|
EP2531509B1
(en)
|
2010-02-03 |
2016-10-05 |
Incyte Holdings Corporation |
Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors
|
US8901137B2
(en)
|
2010-02-09 |
2014-12-02 |
Exelixis, Inc. |
Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors
|
TWI766281B
(en)
|
2010-03-10 |
2022-06-01 |
美商英塞特控股公司 |
Piperidin-4-yl azetidine derivatives as jak1 inhibitors
|
JP5583845B2
(en)
*
|
2010-04-28 |
2014-09-03 |
ブリストル−マイヤーズ スクイブ カンパニー |
Imidazopyridazinyl compounds and their use against cancer
|
CN103391936B
(en)
*
|
2010-04-30 |
2016-04-27 |
国立大学法人东京大学 |
Carcinostatic agent
|
KR102132405B1
(en)
|
2010-05-20 |
2020-07-09 |
어레이 바이오파마 인크. |
Macrocyclic compounds as trk kinase inhibitors
|
PE20130216A1
(en)
|
2010-05-21 |
2013-02-27 |
Incyte Corp |
TOPICAL FORMULATION FOR A JAK INHIBITOR
|
JP5917544B2
(en)
|
2010-11-19 |
2016-05-18 |
インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation |
Heterocyclic substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
|
AR083933A1
(en)
|
2010-11-19 |
2013-04-10 |
Incyte Corp |
PIRROLOPIRIDINE AND PIRROLOPIRIMIDINE DERIVATIVES REPLACED WITH CYCLOBUTILO AS JAK INHIBITORS
|
MX339899B
(en)
|
2011-02-25 |
2016-06-16 |
Array Biopharma Inc |
Triazolopyridine compounds as pim kinase inhibitors.
|
JP6121991B2
(en)
|
2011-05-17 |
2017-04-26 |
バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH |
Amino-substituted imidazopyridazines as MKNK1 kinase inhibitors
|
CN103717604B
(en)
|
2011-06-01 |
2016-06-01 |
拜耳知识产权有限责任公司 |
Replace aminooimidazole and pyridazine
|
EA201490042A1
(en)
|
2011-06-20 |
2014-10-30 |
Инсайт Корпорейшн |
AZETIDINYL-PHENYL-, PYRIDYL- OR PYRAZYNYLKARBOXAMID DERIVATIVES AS INHIBITORS
|
US9284319B2
(en)
|
2011-06-22 |
2016-03-15 |
Bayer Intellectual Property Gmbh |
Heterocyclyl aminoimidazopyridazines
|
WO2013005041A1
(en)
*
|
2011-07-07 |
2013-01-10 |
Centro Nacional De Investigaciones Oncológicas (Cnio) |
Tricyclic heterocyclic compounds as kinase inhibitors
|
ES2671748T3
(en)
|
2011-07-21 |
2018-06-08 |
Tolero Pharmaceuticals, Inc. |
Heterocyclic protein kinase inhibitors
|
US9260425B2
(en)
*
|
2011-08-12 |
2016-02-16 |
Genetech, Inc. |
Pyrazolo[3,4-c]pyridine compounds and methods of use
|
TW201313721A
(en)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
Cyclohexyl azetidine derivatives as JAK inhibitors
|
UA117092C2
(en)
|
2011-09-06 |
2018-06-25 |
Байєр Інтеллектуал Проперті Гмбх |
Amino-substituted imidazopyridazines
|
UA111854C2
(en)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS
|
US9320737B2
(en)
|
2011-09-23 |
2016-04-26 |
Bayer Intellectual Property Gmbh |
Substituted imidazopyridazines
|
AU2012314035B2
(en)
*
|
2011-09-30 |
2016-12-15 |
Oncodesign S.A. |
Macrocyclic LRRK2 kinase inhibitors
|
CN103930427B
(en)
|
2011-09-30 |
2016-03-09 |
昂科迪塞恩股份有限公司 |
Large ring FLT3 kinase inhibitor
|
JP6057907B2
(en)
*
|
2011-10-04 |
2017-01-11 |
株式会社ヤクルト本社 |
Pharmaceuticals containing thiazolidine derivatives or their salts as active ingredients
|
WO2013087581A1
(en)
|
2011-12-12 |
2013-06-20 |
Bayer Intellectual Property Gmbh |
Amino-substituted imidazopyridazines
|
EP2858993B1
(en)
|
2012-03-29 |
2018-01-10 |
Bayer Intellectual Property GmbH |
Amino-substituted imidazopyridazines
|
US10280168B2
(en)
|
2012-03-30 |
2019-05-07 |
Agency For Science, Technology And Research |
Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof
|
GB201205669D0
(en)
|
2012-03-30 |
2012-05-16 |
Agency Science Tech & Res |
Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
|
WO2013149909A1
(en)
|
2012-04-04 |
2013-10-10 |
Bayer Pharma Aktiengesellschaft |
Amino-substituted imidazopyridazines
|
AR091079A1
(en)
|
2012-05-18 |
2014-12-30 |
Incyte Corp |
DERIVATIVES OF PIRROLOPIRIMIDINA AND PIRROLOPIRIDINA REPLACED WITH PIPERIDINILCICLOBUTILO AS JAK INHIBITORS
|
TWI585088B
(en)
*
|
2012-06-04 |
2017-06-01 |
第一三共股份有限公司 |
Imidazo[1,2-b]pyridazine analogues as kinase inhibitors
|
WO2014004376A2
(en)
|
2012-06-26 |
2014-01-03 |
Del Mar Pharmaceuticals |
Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
|
SG11201503695XA
(en)
|
2012-11-15 |
2015-06-29 |
Incyte Corp |
Sustained-release dosage forms of ruxolitinib
|
CA2889919C
(en)
|
2012-11-16 |
2021-08-17 |
University Health Network |
Pyrazolopyrimidine compounds
|
ME03042B
(en)
|
2012-11-19 |
2018-10-20 |
Novartis Ag |
Compounds and compositions for the treatment of parasitic diseases
|
US8871754B2
(en)
|
2012-11-19 |
2014-10-28 |
Irm Llc |
Compounds and compositions for the treatment of parasitic diseases
|
JP2015537017A
(en)
|
2012-11-19 |
2015-12-24 |
バイエル ファーマ アクチエンゲゼルシャフト |
Aminoimidazopyridazines
|
JP6437452B2
(en)
|
2013-01-14 |
2018-12-12 |
インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation |
Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
|
NZ710079A
(en)
|
2013-01-15 |
2020-01-31 |
Incyte Holdings Corp |
Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
|
CA2899352A1
(en)
|
2013-01-30 |
2014-08-07 |
Bayer Pharma Aktiengesellschaft |
Amidoimidazopyridazines as mknk-1 kinase inhibitors
|
JP2016509036A
(en)
|
2013-02-20 |
2016-03-24 |
バイエル・ファルマ・アクティエンゲゼルシャフト |
Substituted imidazo [1,2-B] pyridazines as MKNK1 inhibitors
|
HUE057262T2
(en)
|
2013-03-06 |
2022-04-28 |
Incyte Holdings Corp |
Processes and intermediates for making a jak inhibitor
|
WO2014138692A1
(en)
|
2013-03-07 |
2014-09-12 |
Califia Bio, Inc. |
Mixed lineage kinase inhibitors and method of treatments
|
AU2014230125A1
(en)
*
|
2013-03-15 |
2015-10-29 |
Oncodesign S.A. |
Macrocyclic salt-inducible kinase inhibitors
|
JP6023630B2
(en)
*
|
2013-04-03 |
2016-11-09 |
株式会社ヤクルト本社 |
Thiazolone derivatives
|
KR20160061911A
(en)
|
2013-04-08 |
2016-06-01 |
데니스 엠. 브라운 |
Therapeutic benefit of suboptimally administered chemical compounds
|
AU2014290012B2
(en)
*
|
2013-07-19 |
2020-01-16 |
Onyx Therapeutics, Inc. |
Peptide epoxyketone proteasome inhibitors in combination with PIM kinase inhibitors for treatment of cancers
|
US9655854B2
(en)
|
2013-08-07 |
2017-05-23 |
Incyte Corporation |
Sustained release dosage forms for a JAK1 inhibitor
|
AR097431A1
(en)
|
2013-08-23 |
2016-03-16 |
Incyte Corp |
FUR CARBOXAMIDE COMPOUNDS AND TIENOPIRIDINE USEFUL AS PIM KINASE INHIBITORS
|
AR097543A1
(en)
*
|
2013-09-06 |
2016-03-23 |
Lexicon Pharmaceuticals Inc |
COMPOUNDS BASED ON IMIDAZO [1,2-b] PIRIDAZINE, COMPOSITIONS THAT INCLUDE THEM AND THEIR METHODS OF USE
|
CA2936024A1
(en)
|
2014-01-09 |
2015-07-16 |
Bayer Pharma Aktiengesellschaft |
Amido-substituted imidazopyridazines useful in the treatment of hyper-proliferative and/or angiogenesis disorders
|
CN103864800A
(en)
*
|
2014-04-03 |
2014-06-18 |
定陶县友帮化工有限公司 |
Synthesis method for 6-chloroimidazo[1,2-b] pyridazine
|
US9498467B2
(en)
|
2014-05-30 |
2016-11-22 |
Incyte Corporation |
Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
|
GB201410817D0
(en)
|
2014-06-17 |
2014-07-30 |
Ucb Biopharma Sprl And Katholieke Universiteit Leuven K U Leuven R & D |
Therapeutic agents
|
US9580418B2
(en)
|
2014-07-14 |
2017-02-28 |
Incyte Corporation |
Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
|
US9822124B2
(en)
|
2014-07-14 |
2017-11-21 |
Incyte Corporation |
Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
|
EA032872B1
(en)
*
|
2014-09-17 |
2019-07-31 |
Онкодизайн С.А. |
Macrocyclic rip2 kinase inhibitors
|
RS64122B1
(en)
|
2014-11-16 |
2023-05-31 |
Array Biopharma Inc |
Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
|
WO2016196244A1
(en)
|
2015-05-29 |
2016-12-08 |
Incyte Corporation |
Pyridineamine compounds useful as pim kinase inhibitors
|
TWI734699B
(en)
|
2015-09-09 |
2021-08-01 |
美商英塞特公司 |
Salts of a pim kinase inhibitor
|
US9920032B2
(en)
|
2015-10-02 |
2018-03-20 |
Incyte Corporation |
Heterocyclic compounds useful as pim kinase inhibitors
|
BR112018008357A2
(en)
|
2015-10-26 |
2018-11-27 |
Array Biopharma Inc |
dot mutations in trk inhibitor resistant cancer and related methods
|
US10525047B2
(en)
|
2016-03-25 |
2020-01-07 |
University Of Maryland, Baltimore County |
PIM kinase inhibitors in combination with RNA splicing modulators/inhibitors for treatment of cancers
|
US10045991B2
(en)
|
2016-04-04 |
2018-08-14 |
Loxo Oncology, Inc. |
Methods of treating pediatric cancers
|
AU2017246554B2
(en)
|
2016-04-04 |
2022-08-18 |
Loxo Oncology, Inc. |
Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
|
WO2017176744A1
(en)
|
2016-04-04 |
2017-10-12 |
Loxo Oncology, Inc. |
Methods of treating pediatric cancers
|
HRP20230704T1
(en)
|
2016-05-18 |
2023-10-27 |
Loxo Oncology, Inc. |
Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
|
JOP20190092A1
(en)
|
2016-10-26 |
2019-04-25 |
Array Biopharma Inc |
PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF
|
JOP20190213A1
(en)
|
2017-03-16 |
2019-09-16 |
Array Biopharma Inc |
Macrocyclic compounds as ros1 kinase inhibitors
|
MX2019012431A
(en)
|
2017-04-21 |
2020-08-03 |
Ikena Oncology Inc |
Indole ahr inhibitors and uses thereof.
|
ES2930081T3
(en)
*
|
2017-08-11 |
2022-12-07 |
Teligene Ltd |
Substituted Pyrazolopyrimidines Useful as Kinase Inhibitors
|
KR20200051646A
(en)
|
2017-08-17 |
2020-05-13 |
이케나 온콜로지, 인코포레이티드 |
AHR inhibitors and uses thereof
|
US11319320B2
(en)
|
2017-11-06 |
2022-05-03 |
Snap Bio, Inc. |
PIM kinase inhibitor compositions, methods, and uses thereof
|
AR113922A1
(en)
|
2017-12-08 |
2020-07-01 |
Incyte Corp |
LOW DOSE COMBINATION THERAPY FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS
|
CN112105608B
(en)
|
2018-01-30 |
2023-07-14 |
因赛特公司 |
Process for the preparation of (1- (3-fluoro-2- (trifluoromethyl) isonicotinyl) piperidin-4-one
|
AU2019245420A1
(en)
|
2018-03-30 |
2020-11-12 |
Incyte Corporation |
Treatment of hidradenitis suppurativa using JAK inhibitors
|
CA3095580A1
(en)
|
2018-04-13 |
2019-10-17 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer
|
KR20210146290A
(en)
|
2019-02-12 |
2021-12-03 |
스미토모 다이니폰 파마 온콜로지, 인크. |
Formulations comprising heterocyclic protein kinase inhibitors
|
IL293085A
(en)
|
2019-11-22 |
2022-07-01 |
Incyte Corp |
Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor
|
EP4065582A1
(en)
|
2019-11-26 |
2022-10-05 |
Ikena Oncology, Inc. |
Polymorphic carbazole derivatives and uses thereof
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
JP2023541262A
(en)
*
|
2020-09-14 |
2023-09-29 |
ザ ユニバーシティー オブ サセックス |
Small molecule inhibitor of Lemur tyrosine kinase 3
|
EP4267137A1
(en)
*
|
2020-12-22 |
2023-11-01 |
Enliven Inc. |
Lactam (hetero)arylfusedpyrimidine derivatives as inhibitors of erbb2
|
CN114409656B
(en)
*
|
2021-02-08 |
2022-09-23 |
杭州邦顺制药有限公司 |
PIM kinase inhibitors
|
WO2023057394A1
(en)
*
|
2021-10-04 |
2023-04-13 |
Forx Therapeutics Ag |
N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
|
WO2024097653A1
(en)
|
2022-10-31 |
2024-05-10 |
Sumitomo Pharma America, Inc. |
Pim1 inhibitor for treating myeloproliferative neoplasms
|